ResMed (ASX:RMD) Cyclically Adjusted FCF per Share: A$0.84 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:RMD ResMed Inc ASX:RMD
98 GF Score
Price A$27.74
GF Value A$40.60
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is ResMed Cyclically Adjusted FCF per Share?

ResMed ASX:RMD -3.04% 98 Cyclically Adjusted FCF per Share is A$0.84 as of Mar. 2026. GuruFocus rates ASX:RMD with a GF Score™ of 98/100 and a GF Value™ of A$40.60 (Significantly Undervalued). The stock has 1 warning sign investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

ResMed's adjusted free cash flow per share for the three months ended in Mar. 2026 was A$0.503. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is A$0.84 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ResMed's average Cyclically Adjusted FCF Growth Rate was 19.20% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 15.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 12.10% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 13.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of ResMed was 100.00% per year. The lowest was 8.30% per year. And the median was 20.10% per year.

As of today (2026-07-16), ResMed's current stock price is A$27.74. ResMed's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was A$0.84. ResMed's Cyclically Adjusted Price-to-FCF of today is 33.02.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.30. And the median was 51.55.


ResMed  (ASX:RMD) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

ResMed's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=27.74/0.84
=33.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of ResMed was 91.58. The lowest was 32.30. And the median was 51.55.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


ResMed Cyclically Adjusted FCF per Share Related Terms


ResMed Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for ResMed's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ResMed Cyclically Adjusted FCF per Share Chart

ResMed Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.49 0.53 0.65 0.79

ResMed Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.77 0.79 0.81 0.82 0.84

ASX:RMD vs MDLN, WST, BDX: Cyclically Adjusted FCF per Share Comparison

For the Medical Instruments & Supplies subindustry, ResMed's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ResMed Cyclically Adjusted Price-to-FCF vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ResMed's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where ResMed's Cyclically Adjusted Price-to-FCF falls into.


ASX:RMD
98GF Score
ResMed Inc ASX:RMD
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ResMed Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ResMed's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.503/330.2130*330.2130
=0.503

Current CPI (Mar. 2026) = 330.2130.

ResMed Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.120 241.018 0.164
201609 0.064 241.428 0.088
201612 0.099 241.432 0.135
201703 0.047 243.801 0.064
201706 0.111 244.955 0.150
201709 0.066 246.819 0.088
201712 0.104 246.524 0.139
201803 0.120 249.554 0.159
201806 0.101 251.989 0.132
201809 0.031 252.439 0.041
201812 0.105 251.233 0.138
201903 0.120 254.202 0.156
201906 0.117 256.143 0.151
201909 0.139 256.759 0.179
201912 0.042 256.974 0.054
202003 0.229 258.115 0.293
202006 0.306 257.797 0.392
202009 0.119 260.280 0.151
202012 0.120 260.474 0.152
202103 0.149 264.877 0.186
202106 0.175 271.696 0.213
202109 -0.091 274.310 -0.110
202112 0.171 278.802 0.203
202203 0.060 287.504 0.069
202206 0.046 296.311 0.051
202209 0.013 296.808 0.014
202212 0.097 296.797 0.108
202303 0.255 301.836 0.279
202306 0.201 305.109 0.218
202309 0.259 307.789 0.278
202312 0.251 306.746 0.270
202403 0.392 312.332 0.414
202406 0.422 314.175 0.444
202409 0.306 315.301 0.320
202412 0.305 315.605 0.319
202503 0.598 319.799 0.617
202506 0.527 322.561 0.540
202509 0.425 324.800 0.432
202512 0.314 324.054 0.320
202603 0.503 330.213 0.503

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of A$0.84 mean?
ResMed (ASX:RMD) has a Cyclically Adjusted FCF per Share of A$0.84 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors.
Is ResMed's Cyclically Adjusted FCF per Share too high?
ResMed's current Cyclically Adjusted FCF per Share is A$0.84. Overall, ResMed has a GF Score™ of 98/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ResMed's Cyclically Adjusted FCF per Share compare to MDLN and WST?
ResMed's Cyclically Adjusted FCF per Share of A$0.84 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted FCF per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on ResMed and its competitors. ResMed's current Cyclically Adjusted FCF per Share is A$0.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ResMed stock overvalued right now?
Based on GuruFocus' analysis, ResMed (ASX:RMD) is currently considered Significantly Undervalued. The stock's GF Value™ is A$40.60, compared to a current price of A$27.74 — trading 31.7% below its estimated fair value. The current Cyclically Adjusted FCF per Share is A$0.84. ResMed's overall GF Score™ is 98/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For ResMed (ASX:RMD), the current Cyclically Adjusted FCF per Share is A$0.84 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ResMed (ASX:RMD) Overvalued in 2026?

Based on GuruFocus' analysis, ResMed stock appears to be undervalued. The current stock price of A$27.74 is trading 31.7% below its estimated GF Value™ of A$40.60. GuruFocus considers ResMed to be Significantly Undervalued.

Key valuation signals for ASX:RMD:

  • Cyclically Adjusted FCF per Share: A$0.84
  • GF Value™: A$40.60 vs. price of A$27.74 (31.7% below fair value)
  • GF Score™: 98/100 with 1 warning sign

No single metric tells the full story. See the ASX:RMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ResMed Business Description

Address 9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with aging populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two-thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan, and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor, and payer in the out-of-hospital setting.
98GF Score

Get the complete analysis for ASX:RMD

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$27.74
Price
A$40.60
GF Value